PMID- 30101913
OWN - NLM
STAT- MEDLINE
DCOM- 20190208
LR  - 20200225
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Print)
IS  - 0918-2918 (Linking)
VI  - 57
IP  - 24
DP  - 2018 Dec 15
TI  - Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by 
      Light Chain Deposition Disease.
PG  - 3651-3657
LID - 10.2169/internalmedicine.1018-18 [doi]
AB  - Light chain deposition disease (LCDD) is a rare systemic disorder caused by the 
      deposition of light chain immunoglobulins, which often results in renal 
      impairment associated with either nephrotic syndrome or asymptomatic proteinuria. 
      B-cell neoplasms, such as multiple myeloma and lymphoproliferative disorders, are 
      well-known underlying diseases in LCDD. Some chemotherapy regimens have been 
      reported, but both evidence-based treatment and management for LCDD have yet to 
      be established. We herein report three cases of LCDD treated with 
      lenalidomide-based therapy, resulting in hematologic responses accompanied by a 
      significant reduction in proteinuria and improvement in the renal function. We 
      recommend lenalidomide-based therapy for renal impairment caused by LCDD.
FAU - Kimura, Satoshi
AU  - Kimura S
AD  - Department of Hematology, Fukushima Medical University, Japan.
FAU - Ohkawara, Hiroshi
AU  - Ohkawara H
AD  - Department of Hematology, Fukushima Medical University, Japan.
FAU - Ogawa, Kazuei
AU  - Ogawa K
AD  - Department of Hematology, Fukushima Medical University, Japan.
FAU - Tanaka, Mizuko
AU  - Tanaka M
AD  - Department of Diagnostic Pathology, Fukushima Medical University, Japan.
FAU - Sano, Takahiro
AU  - Sano T
AD  - Department of Hematology, Fukushima Medical University, Japan.
FAU - Harada-Shirado, Kayo
AU  - Harada-Shirado K
AD  - Department of Hematology, Fukushima Medical University, Japan.
FAU - Takahashi, Hiroshi
AU  - Takahashi H
AD  - Department of Hematology, Fukushima Medical University, Japan.
FAU - Ueda, Koki
AU  - Ueda K
AD  - Department of Hematology, Fukushima Medical University, Japan.
FAU - Shichishima-Nakamura, Akiko
AU  - Shichishima-Nakamura A
AD  - Department of Hematology, Fukushima Medical University, Japan.
FAU - Matsumoto, Hayato
AU  - Matsumoto H
AD  - Department of Hematology, Fukushima Medical University, Japan.
FAU - Ikeda, Kazuhiko
AU  - Ikeda K
AD  - Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical 
      University, Japan.
FAU - Kazama, Junichiro James
AU  - Kazama JJ
AD  - Department of Nephrology and Hypertension, Fukushima Medical University, Japan.
FAU - Hashimoto, Yuko
AU  - Hashimoto Y
AD  - Department of Diagnostic Pathology, Fukushima Medical University, Japan.
FAU - Ikezoe, Takayuki
AU  - Ikezoe T
AD  - Department of Hematology, Fukushima Medical University, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20180810
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (Immunoglobulin Light Chains)
RN  - 0 (Immunologic Factors)
RN  - F0P408N6V4 (Lenalidomide)
SB  - IM
MH  - Aged
MH  - Humans
MH  - *Immunoglobulin Light Chains
MH  - Immunologic Factors/*therapeutic use
MH  - Lenalidomide/*therapeutic use
MH  - Male
MH  - Paraproteinemias/*complications
MH  - Proteinuria/drug therapy
MH  - Renal Insufficiency/*drug therapy/*etiology
PMC - PMC6355407
OTO - NOTNLM
OT  - lenalidomide
OT  - light chain deposition disease
OT  - nephrotic syndrome
EDAT- 2018/08/14 06:00
MHDA- 2019/02/09 06:00
PMCR- 2018/12/15
CRDT- 2018/08/14 06:00
PHST- 2018/08/14 06:00 [pubmed]
PHST- 2019/02/09 06:00 [medline]
PHST- 2018/08/14 06:00 [entrez]
PHST- 2018/12/15 00:00 [pmc-release]
AID - 10.2169/internalmedicine.1018-18 [doi]
PST - ppublish
SO  - Intern Med. 2018 Dec 15;57(24):3651-3657. doi: 10.2169/internalmedicine.1018-18. 
      Epub 2018 Aug 10.